Journal of Hepatology and Gastrointestinal disorders
Open Access
ISSN: 2475-3181
+44-20-4587-4809
ISSN: 2475-3181
+44-20-4587-4809
Viorela Diana Artene
Carol Davila University of Medicine and Pharmacy, Romania
Posters & Accepted Abstracts: J Hepatol Gastroint Dis
Sarcopenic obesity is an independent breast cancer prognostic factor that increases recurrence, metastasis, BC-specific and all-cause mortality risks. To test the efficacy of a moderately lower carb diet based on eating only when hungry foods naturally high in protein, high quality fatty acids and carbohydrates, calcium, pre and probiotics we followed the weight and body composition evolution of 614 breast cancer patients for 24 months. 331 patients were randomly allocated to the control group with no oncology nutrition advice besides the recommendation to avoid weight gain. And 283 patients were randomly allocated to the intervention group and asked to follow the proposed diet. We measured their weight and body composition and we compared results at 24 months between intervention and control groups. Then we analyzed the results based on the administered oncology treatment type and on patients�?? related comorbidities, lifestyle and personal characteristics. Sarcopenic obesity solutions�?? efficacy was influenced by AET type patients on letrozol having best results; de novo thiroidian disease decreases the ability to lose fat; depression decreases the ability to lose fat; statins when co administrated throughout exemestane treatment decreased the ability to lose fat; sleep disturbances increase sarcopenia. And was not influenced by chemotherapy or radiotherapy administration, the type of surgery, cardiovascular disease and smoking or by the chronic dieting hystory of the patients. Oncology nutrition interventions can successfully counteract sarcopenic obesity during AET regardless of the oncology treatment administered, but the efficacy of the intervention can be influenced by patients�?? comorbidities.
E-mail: artene.diana@yahoo.com